ARCHIVES

mTOR Inhibitor Improves PFS In Metastatic Sarcoma Patients

This article is from The Cancer Letter archive.

Vol. 34 No. 2 | February 25, 2011

Download PDF Visit The Full Archive

Related Articles

NCI Cooperative Group, Cancer Center Trials Listed

June 29, 2007

Clinical Trials: Phase I Trial of Karenitecin Begins, BioNumerik Says

March 5, 1999

Proposed Surveillance Model Aims To Reduce Post-Treatment Pain

April 27, 2012

Breast Cancer Incidence Reduced 45% In Tamoxifen Arm Of BCPT; Trial Unblinded

April 10, 1998

Herceptin Regimen Minus Adriamycin Increases Survival With Less Toxicity

October 28, 2011

NCI Bypass Budget Seeks $3.64 Billion

January 20, 1995